 | |
| Clinical data | |
|---|---|
| Trade names | Ampalex |
| Pharmacokinetic data | |
| Eliminationhalf-life | 45 minutes |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.237.047 |
| Chemical and physical data | |
| Formula | C14H15N3O |
| Molar mass | 241.294 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
CX-516 is anampakine andnootropic that acts as anAMPA receptorpositive allosteric modulator and had been undergoingdevelopment by a collaboration betweenCortex,Shire, andServier. It was studied as a potential treatment forAlzheimer's disease under the brand nameAmpalex, and was also being examined as a treatment forADHD.
CX-516 was the first ampakine compound developed by Cortex and while it showed goodin vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such asfarampator andCX-717 are compared to.
